AZAgnieszka Zalewska

Agnieszka Zalewska

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Agnieszka Zalewska has a total of 13 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    ONE PATHWAY, INFINITE POTENTIAL? THE FUTURE OF GLP-1 THERAPIES: A 2026 CLINICAL UPDATE

    by Magdalena Fidelis, Maria Wojcieszek, Katarzyna Gondek, Dominika Gacka, Agnieszka Zalewska, Aleksandra Mączyńska, Noor Alhuda Al-Karawi, Paulina Kędziorek, Zuzanna Tanç

    Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have advanced from incretin-based therapies for type 2 diabetes to multifaceted treatments addressing obesity, cardiovascular disease, and emerging neuropsychiatric conditions. This review examines their physiological mechanisms, pharmacological profiles, and clinical outcomes based on data through early 2026. GLP-1 RAs mimic the incretin effect, enhancing insulin secretion, delaying gastric emptying, and modulating central reward pathways in the mesolimbic system. Approved agents like semaglutide and tirzepatide achieve 15-25% weight loss, reduce major adverse cardiovascular events by 12-26%, and show promise in heart failure with preserved ejection fraction and chronic kidney disease. Recent trials indicate potential in alcohol use disorder, with semaglutide reducing heavy drinking and cravings, though cognitive benefits in major depressive disorder remain unproven. Safety analyses from large cohorts (2024-2025) confirm no increased thyroid cancer risk (HR 0.81-0.93), and FDA reviews (2026) find no causal suicidality link. Overall, GLP-1 RAs bridge metabolic and behavioral health, supporting a unified view of energy regulation. Ongoing research on patient responders and targeted analogues will guide their integration into care for metabolic psychiatry, emphasizing balanced risk assessment.

  • Open Access

    THE EYE AS AN INTERFACE: HOW XR, AI AND AUTOMATION CHANGED OPHTHALMIC PRACTICE (2015–2025)

    by Magdalena Fidelis, Maria Wojcieszek, Katarzyna Gondek, Dominika Gacka, Agnieszka Zalewska, Aleksandra Mączyńska, Noor Alhuda Al-Karawi, Paulina Kędziorek, Zuzanna Tanç

    This review examines the integration of emerging digital technologies in ophthalmology to address global vision impairment affecting over 2.2 billion people, with a focus on scalability, equity, and sustainability amid rising age-related pathologies like AMD, glaucoma, and DR. Objectives: Synthesize evidence from 2015-2025 on xVR/AR, AI, teleophthalmology, robotics, and nanotechnology, evaluating clinical efficacy, economic viability, ethical implications, and environmental impact. Methods: Systematic literature search across PubMed, Scopus, IEEE Xplore, and Web of Science using Boolean keywords for targeted technologies. Inclusion: peer-reviewed studies with quantitative outcomes (e.g., visual acuity, AUC, CO2 reductions); exclusion: pre-2015, non-English, non-clinically validated works. Data extraction emphasized study design, interventions, outcomes, biases, and ethics. Key Findings: VR dichoptic therapy yields 1.8 logMAR improvements in amblyopia with 88% adherence, surpassing patching. AI achieves >90% sensitivity for DR screening, mitigated by generative models for bias. Teleophthalmology resolves 75% cases remotely, saving up to 176 kg CO2/patient. Robotics enable 5%); 3D bioprinting pioneers corneal implants. Conclusions: These technologies foster precise, decentralized eye care, but require addressing biases, regulations, and access barriers for equitable global impact.

  • Open Access

    PRECISION MEDICINE FOR RYR1-RELATED MYOPATHIES: A COMPREHENSIVE REVIEW OF GENE EDITING, PHARMACOLOGICAL INTERVENTIONS, AND SOCIETAL IMPLICATIONS

    by Magdalena Fidelis, Maria Wojcieszek, Katarzyna Gondek, Dominika Gacka, Agnieszka Zalewska, Aleksandra Mączyńska, Noor Alhuda Al-Karawi, Paulina Kędziorek, Zuzanna Tanç

    Ryanodine receptor 1-related myopathies (RYR1-RM) constitute the most prevalent class of non-dystrophic congenital myopathies, representing a complex intersection of genetic heterogeneity, molecular pathology, and evolving therapeutic paradigms. Characterized by mutations in the RYR1 gene, these disorders manifest across a broad clinical spectrum ranging from static congenital weakness to life-threatening pharmacogenetic traits such as Malignant Hyperthermia Susceptibility (MHS). This review article provides an exhaustive synthesis of the scientific and societal landscape of RYR1-RM as of 2025. We provide a deep mechanistic analysis of the RyR1 channel's structure-function relationship, elucidated through recent cryo-electron microscopy breakthroughs that define the "leaky channel" pathophysiology. We critically evaluate the emerging pharmacological arsenal, including the landmark Phase 1b trial of the Rycal compound ARM210 (S48168), the novel application of epigenetic modulation via 5-aza-2'-deoxycytidine, and the repurposed utility of dantrolene and salbutamol. Furthermore, we dissect the frontier of precision genetic engineering, detailing the mechanics and efficacy of Prime Editing and Twin Prime Editing strategies, alongside the development of myotropic viral vectors (MyoAAV) designed to overcome the delivery barriers inherent to the massive RYR1 gene. Beyond the bench, this report integrates a rigorous social science perspective, analyzing the health economic frameworks (ICER, QALYs) that govern access to orphan drugs, the ethical dimensions of somatic gene editing for non-lethal disabilities, and the transformative role of patient advocacy in the rare disease ecosystem. This multidimensional review aims to serve as a foundational resource for clinicians, researchers, and policymakers navigating the complex transition from supportive care to disease-modifying precision medicine.

  • Open Access

    THE INVISIBLE INTRUDER: A REVIEW OF MICROPLASTICS ACCUMULATION IN HUMAN TISSUES AND IMPLICATIONS FOR PUBLIC HEALTH, WITH EMPHASIS ON REPRODUCTIVE HEALTH

    by Magdalena Fidelis, Agnieszka Zalewska, Maria Zadrożna-Dyńka, Marcin Dyńka, Maria Wojcieszek, Katarzyna Gondek, Dominika Gacka, Aleksandra Mączyńska, Noor Alhuda Al-Karawi, Paulina Kędziorek, et al.

    Global plastic production has led to widespread environmental contamination, with synthetic polymers fragmenting into microplastics (MPs) and nanoplastics (NPs). These particles have been detected in human tissues, raising questions about their health effects. This narrative review synthesizes biomonitoring studies on MP/NP accumulation, with a focus on reproductive systems. Data from recent research show polymers in blood, lungs, placentas, breast milk, testes, and brain, linked to exposure routes such as inhalation and ingestion. The review examines potential translocation across barriers like the placenta and blood-brain barrier, as well as toxicity mechanisms, including endocrine-disrupting chemical release, oxidative stress via the Nrf2 pathway, and cellular disruption. In reproductive health, evidence indicates MP presence in ovarian follicular fluid and associations with reduced sperm quality, suggesting potential contributions to fertility trends. The review also addresses debates on neuro-accumulation and economic costs of related diseases. Findings highlight MPs as a public health concern, calling for policy measures and updated risk assessments.

  • Open Access

    THE HIDDEN COST OF FLEXIBILITY: MUSCULOSKELETAL DISORDERS, TECHNOSTRESS, AND SOCIAL ISOLATION IN THE ERA OF REMOTE WORK

    by Magdalena Fidelis, Agnieszka Zalewska, Maria Zadrożna-Dyńka, Marcin Dyńka, Maria Wojcieszek, Katarzyna Gondek, Dominika Gacka, Aleksandra Mączyńska, Noor Alhuda Al-Karawi, Paulina Kędziorek, et al.

    The global shift to remote and hybrid work models from 2021 to 2025, comparable to the Industrial Revolution in scale, has entrenched flexibility while introducing unintended physiological, psychological, and sociological costs. This narrative review synthesizes data from the International Labour Organization, World Health Organization, Eurofound, and peer-reviewed literature (2020-2025) to analyze these externalities among college-educated workers. Drawing on the Global Survey of Working Arrangements (G-SWA), work-from-home stabilized at 1.27 days/week globally (27% of U.S. workdays), with regional disparities (e.g., 1.5-1.9 days in English-speaking economies vs. 0.5-1.0 in Asia) influencing exposure. The "Infinite Workday" (Microsoft, 2025) - characterized by 117 emails, 153 Teams messages, and 275 daily interruptions - exacerbates issues like Work-Related Musculoskeletal Disorders (WRMSDs, prevalence 61.2%-72%, e.g., neck pain 50.4%-58.9%) and Computer Vision Syndrome (CVS, pooled 69.0%, 95% CI 62.3-75.3). Psychologically, technostress (50-70% prevalence for techno-overload) and Zoom fatigue (40-70%) blur boundaries, while sedentary isolation elevates inflammation (CRP/IL-6) and depression risk (20-43%). Sociologically, women face double burdens (promotion gap 37% vs. 49% for men), Gen Z reports 27% loneliness, and individualism explains 29% WFH variance. Economically, costs include $380.9 billion U.S. MSK healthcare and $9.6 trillion global disengagement opportunity (Gallup, 2025). Without ergonomic (e.g., TuMeke's 42% injury reduction), policy ("Right to Disconnect" reducing stress 10-30%), and cultural interventions, flexibility's dividends risk erosion by chronic morbidity.

  • Hypertension – a global problem requiring a comprehensive approach

    by Agnieszka Zalewska, Anna Litwińska-Kmiecik, Alicja Wiśniewska